drugset
drugset / Trial / NCT04208399

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

NCT04208399 ↗

Phase 1 Completed 16 enrolled Janssen Sciences Ireland UC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in participants with liver cirrhosis and impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.

Timeline

Start
2020-01-09
Primary completion
2021-03-26
Completion
2021-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject bersacapavir Other / unclassified — Oral

Indications

No indication recorded.